HEPATITIS-C INFECTION AMONG INJECTING DRUG-USERS ATTENDING THE NATIONAL DRUG-TREATMENT CENTER

被引：19

作者：

SMYTH, R

KEENAN, E

DORMAN, A

OCONNOR, J

机构：

[1] The Drug Treatment Board, Trinity Court, Dublin 2

来源：

IRISH JOURNAL OF MEDICAL SCIENCE | 1995年 / 164卷 / 04期

关键词：

D O I：

10.1007/BF02967199

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

During a one year period from August 1992 to August 1993, 272 injecting drug users attending the National Drug Treatment Centre were tested for antibody to Hepatitis C Virus with a second generation EIA test. The overall sere-prevalence was 84% (N=229). A significantly greater proportion of females tested positive than males (Female : Male, 94% v 80%, p<0.012), Looking at sere-prevalence of Hepatitis C in relation to duration of intravenous drug misuse, we found that in those patients with a duration of misuse of greater than two years (N=156) the sere-prevalence was 95% and in those with a duration of intravenous drug misuse of less than two years (N=116) the sere-prevalence was 70%. We conclude that needle sharing continues to occur among injecting drug users during their first two years of injecting, despite the existence of harm minimization programmes. Our results would suggest that female injecting drug users are involved in greater at risk behaviour in relation to Hepatitis C than their male counterparts.

引用

页码：267 / 268

页数：2

共 12 条

[1]

Polyuka S., Laufs R., Hepatitis C Virus Antibody Amongst Different Groups at Risk and Patients with Suspected Non-A, Non-B Hepatitis, Infection, 19, 2, pp. 81-4, (1991)

[2]

Von De Hock J.A., Van Hasstrecht M.J., Prevalence, Incidence and Risk Factors of Hepatitis C Virus Infection Among Drug Users in Amsterdam, Journal of Infectious Diseases, 162, 4, pp. 823-6, (1990)

[3]

Brester D., Mouser-Buschaten E.P., Reesink H.W., Roosendall G., Van der Poet C.L., Chamuleau R.A.F.M., Et al., Sexual Transmission of Hepatitis C Virus, Lancet, 342, pp. 210-211, (1993)

[4]

Everhart J.E., Di Bisceglie A.M., Murray L.M., Alter H.J., Melpolder J.J., Kno G., Hoofnagle J.H., Risk for Non-A, Non B, (type C) Hepatitis through Sexual or Household contact with Chronic Carriers, Annals of Internal Medicine, 112, 7, (1990)

[5]

Coughlan C., O'Gorman T., Corbett-Feeney G., McCarthy C.F., Prevalence of Hepatitis C Antibodies in Patients with Liver disorders in the West of Ireland, Irish Medical Journal, 86, pp. 32-33, (1993)

[6]

Donohoe J.G., Munoz A., Nes P.M., Brown D.E., Yawn D.H., McAllister H.A., Et al., The Declining Risk of Post Transfusion Hepatitis C Virus Infection, New England Journal of Medicine, 327, 6, pp. 369-373, (1992)

[7]

Neal, Jones D.A., Killey D., James V., Risk Factors for Hepatitis C Infection. A Case Control Study of Blood Donors in the Trent Region, Epidemiology & Infection, 112, 3, pp. 595-601, (1994)

[8]

Alter M.J., D. W., Polito A.J., Et al., Overview of Hepatitis C Virus Disease and its Detection: Analysis of the role of HCV in Transfusion Associated Hepatitis, Proceedings of 1990 International Symposium on Viral Hepatitis and Liver Disease, (1991)

[9]

Lau J.Y.N., Davis G., Managing Chronic Hepatitis C Virus Infection, British Medical Journal, 306, pp. 469-470, (1993)

[10]

Smyth B., Keenan E., Dorman A., O'Connor J.J., Gender Differences in Needle Sharing Behaviour Patterns, Addiction, 89, (1994)

← 1 2 →